Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
Rascol
O J
OJ
Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France.
Sabatini
U
U
Chollet
F
F
Montastruc
J L
JL
Marc-Vergnes
J P
JP
Rascol
A
A
D000368:Aged; D001058:Apomorphine / Q000627:therapeutic use*; D001921:Brain / Q000098:blood supply; D004298:Dopamine / Q000502:physiology; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009044:Motor Cortex / Q000187:drug effects* / Q000503:physiopathology; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009127:Muscle Rigidity / Q000188:drug therapy / Q000503:physiopathology; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D013003:Somatosensory Cortex / Q000187:drug effects / Q000503:physiopathology; D015899:Tomography, Emission-Computed, Single-Photon
D007980:Levodopa; D001058:Apomorphine; D004298:Dopamine